{
  "docId": "019de074-7472-72bc-8651-e49cc0d0319c",
  "docSlug": "c2a880ad0c526527fe8aa49c40270224",
  "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 28 slides",
  "authorId": "arbutus-biopharma",
  "authorName": "Arbutus Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 18,
  "pageCount": 28,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "appendix_methodology",
  "function": "plan_implementation",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "The slide outlines a clinical trial design with two main arms involving AB-729, VTP-300, and optional Nivolumab.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-7472-72bc-8651-e49cc0d0319c/18",
  "deckHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c",
  "deckJsonHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c.json",
  "deckAnchorHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.7,
        "x": 0.28,
        "y": 0.15
      },
      "kind": "diagram",
      "text": "Clinical trial timeline showing weeks 1-24, 26-48, and follow-up periods.",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a026e117-a1e9-4626-a8bb-1385a4bfb144",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.15,
        "x": 0.04,
        "y": 0.46
      },
      "kind": "image",
      "text": "Vaccitech logo",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0ef9277e-bf7c-4b7f-b5e9-bfa503e0fe75",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.15,
        "x": 0.04,
        "y": 0.9
      },
      "kind": "image",
      "text": "Arbutus Biopharma logo",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7f17e2d2-59e4-4fd5-ab43-8a2079204d17",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.65,
        "x": 0.3,
        "y": 0.6
      },
      "kind": "paragraph",
      "text": "Primary objective: evaluate safety and reactogenicity of AB-729 followed by VTP-300 or placebo. At week 48 all participants who are eligible to discontinue NA therapy will be followed for 48-weeks. Expand the clinical trial to include an additional arm with nivolumab (Opdivo), and dose first patient in this arm in the first half of 2023. Full rights retained by the Companies of their respective product candidates and all costs split equally",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "00c4d725-08c3-4700-8607-6e52580cfa70",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.04,
        "y": 0.575
      },
      "kind": "paragraph",
      "text": "POC Phase 2a clinical trial evaluating AB-729 in combination with Vaccitech's immunotherapeutic, VTP-300, and a NA. Preliminary data expected in 2H '23",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "05c26afe-4dec-46b1-b509-593fa57bfc8b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.2,
        "x": 0.3,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "* awaiting regulatory approval",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a0681b0c-b51b-496b-9098-a8b9b30f52fa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.04,
        "y": 0.21
      },
      "kind": "title",
      "text": "AB-729-202: Phase 2a POC Clinical Trial",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f50341e7-d7df-46de-87a8-2b02eed1fb63",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "1e080998-4edc-4036-9385-133d7a2a689b",
      "evidence": "Visual representation of clinical trial phases over time.",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 28,
      "from": 8,
      "beatId": "8e825e5a-e303-4698-98f8-f2a022a4a5c6",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document presents Arbutus Biopharma's pipeline, including AB-729, AB-101, and AB-161, as a potential solution (p8-28).",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    },
    {
      "to": 28,
      "from": 17,
      "beatId": "f38a537d-5a41-47d5-be5b-904ed8c0f42a",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Impact & Next Steps",
      "beatSlug": "consultants-gambit-impact-next-steps",
      "evidence": "The document outlines the next steps for AB-729 and other pipeline programs (p17-28).",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}